SCHEDULE 13G/A 0000902664-24-006454 0001230239 XXXXXXXX LIVE 3 Common Stock, par value $0.0001 per share 09/30/2025 0001796280 Oric Pharmaceuticals, Inc. 68622P109 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 Rule 13d-1(b) Alkeon Capital Management LLC DE 0.00 4504096.00 0.00 4504096.00 4504096.00 N 4.6 IA OO Panayotis D. Sparaggis X1 0.00 4504096.00 0.00 4504096.00 4504096.00 N 4.6 HC IN Oric Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor, South San Francisco, CA 94080. This statement is filed by: (1) Alkeon Capital Management LLC ("Alkeon"), a Delaware limited liability company and the investment manager to certain funds (the "Alkeon Funds"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Oric Pharmaceuticals, Inc. (the "Company") directly held by the Alkeon Funds; and (2) Panayotis D. Sparaggis ("Mr. Sparaggis"), the Founder and Managing Director of Alkeon, with respect to the shares of Common Stock directly held by the Alkeon Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities and Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein. The address of the business office of each of the Reporting Persons is 350 Madison Avenue, 20th Floor, New York, NY 10017. The Investment Manager is a Delaware limited liability company. Mr. Sparaggis is a citizen of the United States. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 97,122,987 shares of Common Stock outstanding as of August 5, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Securities and Exchange Commission on August 12, 2025. 4.6% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. N Y N See Item 2. The Alkeon Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Alkeon Capital Management LLC /s/ Jennifer Shufro 11/13/2025 Panayotis D. Sparaggis /s/ Panayotis D. Sparaggis 11/13/2025